Claims
- 1. A method for the treatment of cancer of the large intestine, lung or stomach in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound of formula (I) or a pharmaceutically acceptable salt thereof: whereinX is benzimidazolyl which is optionally substituted with 1 to 5 substituents selected from Group A; Y is an oxygen or sulfur atom; Z is a group selected from the following formulae: R is hydrogen, straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, halogen, hydroxyl, nitro, amino which is optionally substituted with one or more substituents selected from Group B, or straight or branched chain C7-C11 aralkyl which is optionally substituted with one or more substituents selected from Group C; m is an integer from 1 to 5 inclusive; Group A selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, straight or branched chain C7-C11 aralkyloxy, halogen, hydroxyl, straight or branched chain C1-C11 aliphatic acyloxy, straight or branched chain C1-C6 alkylthio, straight or branched chain C1-C6 halogenoalkyl, nitro, amino which is optionally substituted with one or more substituents selected from Group B, C6-C10 aryl which is optionally substituted with one or more substituents selected from Group C and straight or branched chain C7-C11 aralkyl which is optionally substituted with one or more substituents selected from Group C; Group B selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C7-C11 aralkyl, C6-C10 aryl, straight or branched chain C1-C11 aliphatic acyl, C8-C12 aromatic aliphatic acyl and C7-C11 aromatic acyl; and Group C selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, halogen, hydroxyl, nitro, C6-C10 aryl, straight or branched chain C1-C6 halogenoalkyl and amino which is optionally substituted with one or more substituents selected from Group B.
- 2. The method of claim 1, wherein X is benzimidazolyl which is optionally substituted with two substituents selected from Group A.
- 3. The method of claim 1, wherein Y is an oxygen atom.
- 4. The method of claim 1, wherein Z is 2,4-dioxothiazolidin-5-ylmethyl.
- 5. The method of claim 1, wherein R is a hydrogen atom.
- 6. The method of claim 1, wherein m is 1.
- 7. The method of claim 1, wherein Group A comprises straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, straight or branched chain C7-C11 aralkyloxy, halogen, hydroxyl, straight or branched chain C1-C7 aliphatic acyloxy, straight or branched chain C1-C6 alkylthio and straight or branched chain C7-C11 aralkyl.
- 8. The method of claim 1, wherein Group A comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy and straight or branched chain C7-C11 aralkyloxy.
- 9. The method of claim 1, wherein Group B comprises straight or branched chain C1-C4 alkyl, straight or branched chain C7-C11 aralkyl and straight or branched chain C1-C7 aliphatic acyloxy.
- 10. The method of claim 1, wherein Group C comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy, halogen, hydroxyl, straight or branched chain C1-C4 halogenoalkyl and amino.
- 11. The method of claim 1, wherein:X is benzimidazolyl which is optionally substituted with two substituents selected from Group A; Y is an oxygen atom; Z is 2,4-dioxothiazolidin-5-ylmethyl; R is a hydrogen atom; m is 1; Group A comprises straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, straight or branched chain C7-C11 aralkyloxy, halogen, hydroxyl, straight or branched chain C1-C7 aliphatic acyloxy, straight or branched chain C1-C6 alkylthio and straight or branched chain C7-C11 aralkyl; Group B comprises straight or branched chain C1-C4 alkyl, straight or branched chain C7-C11 aralkyl and straight or branched chain C1-C7 aliphatic acyloxy; and Group C comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy, halogen, hydroxyl, straight or branched chain C1-C4 halogenoalkyl and amino.
- 12. The method of claim 1, wherein:X is benzimidazolyl which is optionally substituted with two substituents selected from Group A; Y is an oxygen atom; Z is 2,4-dioxothiazolidin-5-ylmethyl; R is a hydrogen atom; m is 1; Group A comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy and straight or branched chain C7-C11 aralkyloxy; Group B comprises straight or branched chain C1-C4 alkyl, straight or branched chain C7-C11 aralkyl and straight or branched chain C1-C7 aliphatic acyloxy; and Group C comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy, halogen, hydroxyl, straight or branched chain C1-C4 halogenoalkyl and amino.
- 13. The method of claim 1 for the treatment of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 14. The method of claim 1 for the treatment of cancer of the large intestine, lung or stomach in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 15. The method of claim 1 for the treatment of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(5-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 16. The method of claim 1 for the treatment of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(1-benzyl-1H-benzimidazol-5-ylmethoxy)benzyl]thiazolidine-2,4-dione.
- 17. The method of claim 1 for the treatment of cancer of the large intestine, lung or stomach in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(5-hydroxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione.
- 18. The method of claim 1 for the treatment of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(5-acetoxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione.
- 19. The method of claim 1 for the treatment, of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-benzyloxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 20. The method of claim 1 for the treatment of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-chloro-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 21. The method of claim 1 for the treatment of cancer in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-methylthio-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl]-thiazolidine-2,4-dione.
- 22. A method for the treatment of cancer of the prostate in a warm-blooded animal, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound of formula (I) or a pharmaceutically acceptable salt thereof: whereinX is benzimidazolyl which is optionally substituted with 1 to 5 substituents selected from Group A; Y is an oxygen or sulfur atom; Z is a group selected from the following formulae: R is hydrogen, straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, halogen, hydroxyl, nitro, amino which is optionally substituted with one or more substituents selected from Group B, or straight or branched chain C7-C11 aralkyl which is optionally substituted with one or more substituents selected from Group C; m is an integer from 1 to 5 inclusive; Group A selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, straight or branched chain C7-C11 aralkyloxy, halogen, hydroxyl, straight or branched chain C1-C11 aliphatic acyloxy, straight or branched chain C1-C6 alkylthio, straight or branched chain C1-C6 halogenoalkyl, nitro, amino which is optionally substituted with one or more substituents selected from Group B, C6-C10 aryl which is optionally substituted with one or more substituents selected from Group C and straight or branched chain C7-C11 aralkyl which is optionally substituted with one or more substituents selected from Group C; Group B selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C7-C11 aralkyl, C6-C10 aryl, straight or branched chain C1-C11 aliphatic acyl, C8-C12 aromatic aliphatic acyl and C7-C11 aromatic acyl; and Group C selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, halogen, hydroxyl, nitro, C6-C10 aryl, straight or branched chain C1-C6 halogenoalkyl and amino which is optionally substituted with one or more substituents selected from Group B.
- 23. The method of claim 22, wherein X is benzimidazolyl which is optionally substituted with two substituents selected from Group A.
- 24. The method of claim 22, wherein Y is an oxygen atom.
- 25. The method of claim 22, wherein Z is 2,4-dioxothiazolidin-5-ylmethyl.
- 26. The method of claim 23, wherein R is a hydrogen atom.
- 27. The method of claim 22, wherein m is 1.
- 28. The method of claim 22, wherein Group A comprises straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, straight or branched chain C7-C11 aralkyloxy, halogen, hydroxyl, straight or branched chain C1-C7 aliphatic acyloxy, straight or branched chain C1-C6 alkylthio and straight or branched chain C7-C11 aralkyl.
- 29. The method of claim 22, wherein Group A comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy and straight or branched chain C7-C11 aralkyloxy.
- 30. The method of claim 22, wherein Group B comprises straight or branched chain C1-C4 alkyl, straight or branched chain C7-C11 aralkyl and straight or branched chain C1-C7 aliphatic acyloxy.
- 31. The method of claim 22, wherein Group C comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy, halogen, hydroxyl, straight or branched chain C1-C4 halogenoalkyl and amino.
- 32. The method of claim 22, wherein:X is benzimidazolyl which is optionally substituted with two substituents selected from Group A; Y is an oxygen atom; Z is 2, 4-dioxothiazolidin-5-ylmethyl; R is a hydrogen atom; m is 1; Group A comprises straight or branched chain C1-C6 alkyl, straight or branched chain C1-C6 alkoxy, straight or branched chain C7-C11 aralkyloxy, halogen, hydroxyl, straight or branched chain C1-C7 aliphatic acyloxy, straight or branched chain C1-C6 alkylthio and straight or branched chain C7-C11 aralkyl; Group B comprises straight or branched chain C1-C4 alkyl, straight or branched chain C7-C11 aralkyl and straight or branched chain C1-C7 aliphatic acyloxy; and Group C comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy, halogen, hydroxyl, straight or branched chain C1-C4 halogenoalkyl and amino.
- 33. The method of claim 23, wherein:X is benzimidazolyl which is optionally substituted with two substituents selected from Group A; Y is an oxygen atom; Z is 2,4-dioxothiazolidin-5-ylmethyl; R is a hydrogen atom; m is 1; Group A comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy and straight or branched chain C7-C11 aralkyloxy; Group B comprises straight or branched chain C1-C4 alkyl, straight or branched chain C7-C11 aralkyl and straight or branched chain C1-C7 aliphatic acyloxy; and Group C comprises straight or branched chain C1-C4 alkyl, straight or branched chain C1-C4 alkoxy, halogen, hydroxyl, straight or branched chain C1-C4 halogenoalkyl and amino.
- 34. The method of claim 22, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 35. The method of claim 22, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 36. The method of claim 22, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(5-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 37. The method of claim 22, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(1-benzyl-1H-benzimidazol-5-ylmethoxy)benzyl]thiazolidine-2,4-dione.
- 38. The method of claim 22, comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(5-hydroxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione.
- 39. The method of claim 22 comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(5-acetoxy-1,4,6,7-tetramethyl-1H-benzimidazol-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione.
- 40. The method of claim 22 comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-benzyloxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 41. The method of claim 23 comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-chloro-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
- 42. The method of claim 22 comprising administering to said warm-blooded animal in need of said treatment a pharmacologically effective amount of a fused heterocyclic compound or a pharmaceutically acceptable salt thereof, wherein said fused heterocyclic compound is 5-[4-(6-methylthio-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione.
Priority Claims (1)
Number |
Date |
Country |
Kind |
11-204476 |
Jul 1999 |
JP |
|
Parent Case Info
This application is a continuation-in-part of International Application PCT/JP00/04858 filed Jul. 19, 2000 (not published in English) which is incorporated herein by this reference.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5734067 |
Jinno et al. |
Mar 1998 |
A |
5886014 |
Fujita et al. |
Mar 1999 |
A |
6207690 |
Urban et al. |
Mar 2001 |
B1 |
6432993 |
Fujita et al. |
Aug 2002 |
B1 |
Foreign Referenced Citations (5)
Number |
Date |
Country |
1022272 |
Jul 2000 |
EP |
5-276895 |
Oct 1993 |
JP |
8-259438 |
Oct 1996 |
JP |
WO 9610021 |
Apr 1996 |
WO |
WO 9930739 |
Jun 1999 |
WO |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/JP00/04858 |
Jul 2000 |
US |
Child |
10/053136 |
|
US |